Auven Therapeutics Announces Closing of Sale of Ocular Technologies Sarl, Holding Entity for Seciera™ for Treatment of Dry Eye Disease

January 6, 2017
Achievement of primary endpoint of increased tear production and key secondary endpoints in confirmatory Phase 3 clinical trial highlights Seciera’s&trade competitive value proposition, validates Auven’s investment model
Read the full press release

Auven Therapeutics Announces Sale of Ocular Technologies to Sun Pharma

October 26, 2016
- Ocular Technologies’ key development program asset, Seciera™ for the treatment of dry eye disease, is close to completing confirmatory Phase 3 clinical trial.
- Auven to receive $40 million upfront payment, substantial contingent development and commercial milestone payments, and royalties.
Read the full press release

Sun's press release

Auven Therapeutics Announces Completion of Enrollment in Confirmatory Phase 3 Clinical Trial of Seciera (OTX-101) for the Treatment of Dry Eye Disease

August 22, 2016
-Pivotal study to confirm significant improvements in tear production and ocular surface inflammation in patients with dry eye disease, with top-line results anticipated by year-end.
-Seciera poised for significant commercial opportunity as a highly competitive entrant in dry eye disease market.
Read the full press release

Auven Therapeutics Announces Initiation of Confirmatory Phase 3 Clinical Trial of Seciera (OTX-101) for the Treatment of Dry Eye Disease

March 03, 2016
-Study to confirm significant improvements in tear production as sole primary endpoint to support regulatory filing.
-Commercial assessment confirms Seciera has the potential for $1 billion in sales worldwide
Read the full press release

Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA™ for the Treatment of Orphan Disease AA Amyloidosis

January 21, 2016
Auven Therapeutics, a global private equity company focused on accelerated development of breakthrough therapeutic drugs, and BELLUS Health Inc. (TSX:BLU), a drug development company focused on rare diseases, today announced the completion of the KIACTA™ (eprodisate) Phase 3 confirmatory study for the treatment of AA amyloidosis..
Read the full press release

Auven Therapeutics Announces Positive Results from Pivotal Clinical Trial of Seciera (OTX-101) in Dry Eye Disease

November 13, 2015
Auven Therapeutics today announced results from its Phase 2b/3 clinical trial evaluating the safety and efficacy of Seciera (OTX-101), a novel patented nanomicellar formulation of cyclosporine for the treatment of dry eye disease. Read the full press release

Auven Therapeutics Leads $80m ADC Therapeutics Financing

September 2, 2015
Auven Therapeutics today announced that it has led portfolio company ADC Therapeutics’ $80 million private equity placement. Existing investor AstraZeneca participated in the placement alongside Auven Therapeutics and a top-tier group of new European and US-based investors.
Read the full press release

Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

August 20, 2015
Valeant Pharmaceuticals International, Inc. and Sprout Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones.
Read the full press release

ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

June 22, 2015
ADC Therapeutics Sarl, the oncology research and development company focused on Antibody Drug Conjugates - ADCs - targeting major cancers, today announced the appointment of Dr. Chris Martin as its Chief Executive Officer.
Read the full press release

ADC Therapeutics Submits its First IND

March 16, 2015
ADC Therapeutics Sarl, the oncology drug development company focused on Antibody Drug Conjugates "ADCs", today announced that it has filed an Investigational New Drug application "IND" with the US Food and Drug Administration as it moves its pipeline into clinical development. The IND is for a Phase I clinical trial for ADCT-301, a novel antibody drug conjugate targeting CD25, a cell-surface antigen, which is over-expressed in many patients with lymphomas.
Read the full press release